Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania
Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania
复制标题
DOI：
10.1016/s0001-706x(99)00090-x
复制
发表时间：
2000-02-25
期刊：
影响因子：
2.7
通讯作者：
Mpembeni, R
中科院分区：
文献类型：
--
作者：
Gasarasi, DB;Premji, ZG;Mpembeni, R
在鲁菲吉地区的三个村庄进行了急性腺淋巴炎（ADL）的纵向前瞻性监测。每两周对 3000 名 10 岁及以上个体进行抽样监测，为期 12 个月。 ADL 的年发病率为每 1000 人 33 人，男性显着高于女性（分别为 52.7/1000 人和 18.7/1000）。 ADL 发作在 40 岁及以上年龄组中更为频繁。有慢性表现的个体似乎更容易受到 ADL 攻击，占总发作次数的 62.2%。此外，与患有鞘膜积液和“正常暴露”的人相比，患有淋巴水肿的人经历更频繁的急性发作。 ADL 发作次数为每年 1 至 5 次，大多数受影响者 (60.4%) 经历过一次发作。 ADL 发作的平均持续时间为 8.6 天，在 72.5% 的发作中，受影响的个体丧失行为能力，无法进行正常活动，平均持续时间为 3.7 天。与 ADL 发作相关的身体丧失能力强调了淋巴丝虫病作为具有重大社会经济后果的主要公共卫生问题的重要性。 (C) 2000 Elsevier Science B.V. 保留所有权利。
A longitudinal prospective surveillance for acute adenolymphagitis (ADL) was carried out in three villages in Rufiji district. A sample population of 3000 individuals aged 10 years and above was monitored fortnightly for a period of 12 months. The annual incidence of ADL was found to be 33 per 1000 population and was significantly higher in males than females (52.7/1000 and 18.7/1000 respectively). ADL episodes were more frequent in the age group of 40 years and above. Individuals with chronic manifestations seemed to be more vulnerable to ADL attacks with 62.2% of the total episodes occurring in this group. Furthermore, individuals with lymphoedema experienced more frequent acute episodes compared to those with hydrocele and 'normal exposed'. ADL episodes ranged from one to five per annum and the majority of the affected (60.4%) experienced a single episode. The average duration of an ADL episode was 8.6 days and in 72.5% of the episodes the affected individuals were incapacitated and unable to do their normal activities for an average duration of 3.7 days. The physical incapacitation associated with ADL episodes emphasizes the significance of lymphatic filariasis as a major public health problem of substantial socio-economic consequences. (C) 2000 Elsevier Science B.V. All rights reserved.